Cargando…

Neuroprotective Efficacy of a New Brain-Penetrating C-Abl Inhibitor in a Murine Parkinson’s Disease Model

Experimental evidence suggests that oxidative and nitrative mechanisms account for much of the dopaminergic neuronal injury in Parkinson’s disease (PD). The ubiquitously expressed non-receptor tyrosine kinase c-Abl is activated by oxidative stress and thus, may play a role in redox-mediated neurodeg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imam, Syed Z., Trickler, William, Kimura, Shinya, Binienda, Zbigniew K., Paule, Merle G., Slikker, William, Li, Senlin, Clark, Robert A., Ali, Syed F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669292/ https://www.ncbi.nlm.nih.gov/pubmed/23741470 http://dx.doi.org/10.1371/journal.pone.0065129

Ejemplares similares

Molecular Aspects of Dopaminergic Neurodegeneration: Gene-Environment Interaction in Parkin Dysfunction
por: Ali, Syed F., et al.
Publicado: (2011)

Protein Kinases and Parkinson’s Disease
por: Mehdi, Syed Jafar, et al.
Publicado: (2016)

Neuroprotective and Therapeutic Strategies against Parkinson’s Disease: Recent Perspectives
por: Sarkar, Sumit, et al.
Publicado: (2016)

c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson’s Disease
por: Lindholm, Dan, et al.
Publicado: (2016)

Anesthetic-Induced Oxidative Stress and Potential Protection
por: Wang, Cheng, et al.
Publicado: (2010)

The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson’s disease mouse model
por: Lee, Saebom, et al.
Publicado: (2018)

Neuroprotective potential of Cordia dichotoma in Parkinson's syndrome induced by haloperidol: An animal study
por: Bhavani, Keserla, et al.
Publicado: (2023)

Cockayne syndrome protein B interacts with and is phosphorylated by c-Abl tyrosine kinase
por: Imam, Syed Z., et al.
Publicado: (2007)

Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia
por: Okabe, Seiichi, et al.
Publicado: (2014)

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
por: Okabe, Seiichi, et al.
Publicado: (2013)

NS-187 (INNO-406), a Bcr-Abl/Lyn Dual Tyrosine Kinase Inhibitor
por: Niwa, Tomoko, et al.
Publicado: (2007)

Design and Synthesis of Brain Penetrant Glycopeptide Analogues of PACAP With Neuroprotective Potential for Traumatic Brain Injury and Parkinsonism
por: Apostol, Christopher R., et al.
Publicado: (2022)

Positron Emission Tomography with [(18)F]FLT Revealed Sevoflurane-Induced Inhibition of Neural Progenitor Cell Expansion in vivo
por: Liu, Shuliang, et al.
Publicado: (2014)

Effects of silver nanoparticles on human and rat embryonic neural stem cells
por: Liu, Fang, et al.
Publicado: (2015)

c-Abl and Parkinson’s Disease: Mechanisms and Therapeutic Potential
por: Brahmachari, Saurav, et al.
Publicado: (2017)

Proceedings of the Second Annual Conference of the MidSouth Computational Biology and Bioinformatics Society
por: Wren, Jonathan D, et al.
Publicado: (2005)

Ketamine-Induced Neurotoxicity and Changes in Gene Expression in the Developing Rat Brain
por: Liu, Fang, et al.
Publicado: (2011)

Management of penetrating brain injury
por: Kazim, Syed Faraz, et al.
Publicado: (2011)

Neurodegeneration and neuroprotection in Parkinson's disease /
Publicado: (1996)

Perinatal neuroprotection
por: Salmeen, Kirsten E., et al.
Publicado: (2014)

Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity
por: Werner, Milton H., et al.
Publicado: (2021)

Treatment of Parkinson’s disease with biologics that penetrate the blood–brain barrier via receptor-mediated transport
por: Pardridge, William M.
Publicado: (2023)

The Promise of Neuroprotective Agents in Parkinson’s Disease
por: Seidl, Stacey E., et al.
Publicado: (2011)

Neuroprotection in Parkinson’s disease: facts and hopes
por: Salamon, András, et al.
Publicado: (2019)

A microarray study of MPP(+)-treated PC12 Cells: Mechanisms of toxicity (MOT) analysis using bioinformatics tools
por: Xu, Zengjun, et al.
Publicado: (2005)

BCG Vaccine-Induced Neuroprotection in a Mouse Model of Parkinson's Disease
por: Yong, Jing, et al.
Publicado: (2011)

Abl Tyrosine Kinase Phosphorylates Nonmuscle Myosin Light Chain Kinase to Regulate Endothelial Barrier Function
por: Dudek, Steven M., et al.
Publicado: (2010)

Neuroprotective Effects of β-Caryophyllene against Dopaminergic Neuron Injury in a Murine Model of Parkinson’s Disease Induced by MPTP
por: Viveros-Paredes, Juan M., et al.
Publicado: (2017)

Neuroprotective Therapy in Parkinson's Disease: Current Status and New Directions from Experimental and Genetic Clues
por: Lin, William, et al.
Publicado: (2005)

Perinatal neuroprotection update
por: Jelin, Angie C., et al.
Publicado: (2016)

Mitochondrial division inhibitor-1 is neuroprotective in the A53T-α-synuclein rat model of Parkinson’s disease
por: Bido, Simone, et al.
Publicado: (2017)

The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease
por: Karuppagounder, Senthilkumar S., et al.
Publicado: (2014)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Incorporating children's toxicokinetics into a risk framework.
por: Ginsberg, Gary, et al.
Publicado: (2004)

Development of a Physiologically Based Model to Describe the Pharmacokinetics of Methylphenidate in Juvenile and Adult Humans and Nonhuman Primates
por: Yang, Xiaoxia, et al.
Publicado: (2014)

Medical Management of Parkinson’s Disease: Focus on Neuroprotection
por: Boll, Marie-Catherine, et al.
Publicado: (2011)

Neuroprotection by Nrf2 in Parkinson’s disease model
Publicado: (2011)

Mitochondrial Dysfunction in Parkinson's Disease: Pathogenesis and Neuroprotection
por: Mounsey, Ross B., et al.
Publicado: (2010)

Erratum: The promise of neuroprotective agents in Parkinson's disease
por: Seidl, Stacey E., et al.
Publicado: (2013)

Neuroprotective Function of DJ-1 in Parkinson's Disease
por: Ariga, Hiroyoshi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8dthu3nlrq43a9qneiok6am52k